Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme

Liu, Xianping; Chen, Yixin; Geng, Daoying; Li, Haichun; Jiang, Ting; Luo, Zimiao; Wang, Jianhong; Pang, Zhiqing; Zhang, Jun

doi:10.3390/membranes12080744

Cited by 7 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These ligand‐receptor interactions lead to internalization of the aptamer‐containing molecule 115 . This phenomenon has been beautifully demonstrated by Liu and his team, who designed DOX‐loaded, pH‐sensitive PLGA NPs coated with aptamer SL1‐modified red blood cell membranes (RNPs) 116 . SL1 binds specifically to c‐Met, a protein found at high concentrations in GBM U87MG cells, thus enabling the accumulation of DOX in the tumor cells.…”

Section: Strategies To Further Enhance Np‐mediated Gbm Tumor Killingmentioning

confidence: 96%

Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme

Lim

Capinpin

Bolem

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and high mortality, with no curative treatment to date as limited trafficking across the blood–brain barrier (BBB) combined with tumor heterogeneity often leads to therapeutic failure. Although modern medicine poses a wide range of drugs that are otherwise efficacious in treating other tumors, they often do not achieve therapeutic concentrations in the brain, hence driving the need for more effective drug delivery strategies. Nanotechnology, an interdisciplinary field, has been gaining immense popularity in recent years for remarkable advancements such as nanoparticle (NP) drug carriers, which possess extraordinary versatility in modifying surface coatings to home in on target cells, including those beyond the BBB. In this review, we will be highlighting recent developments in biomimetic NPs in GBM therapy and how these allowed us to overcome the physiological and anatomical challenges that have long plagued GBM treatment.

show abstract

Section: Strategies To Further Enhance Np‐mediated Gbm Tumor Killingmentioning

confidence: 96%

Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme

Lim

Capinpin

Bolem

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…In this regard, Ben-Akiva et al synthesized PLGA NPs in anisotropic shapes and coated them in the Red blood cells (RBCs) membrane for more extended blood circulation ( Ben-Akiva et al, 2020 ). In GBM, CM-coated PLGA has been loaded with DOX or docetaxel (DTX) for enhanced chemotherapy in the GBM tumor site ( Chai et al, 2017 ; Zou et al, 2018 ; Liu et al, 2022b ).…”

Section: An Overview On Nps In Gbm Treatmentmentioning

confidence: 99%

“…In GBM, RBC is a popular choice for therapeutic agent encapsulation. For instance, RBC membrane-coated NPs have been designed for the delivery of therapeutic agents, including famous DOX, PLGA ( Chai et al, 2017 ; Ben-Akiva et al, 2020 ; Liu et al, 2022b ), gene therapy agents like DNA and RNA ( Liu et al, 2020a ; Han et al, 2021 ; Li et al, 2022a ), and agents like indocyanine green (ICG) for synergic GBM therapy ( Wang et al, 2020 ; Li et al, 2022a ). RBC membrane-coated NPs could also be used for toxin removal alongside cancer therapy.…”

Section: An Overview On Cm-coating Technologymentioning

confidence: 99%

“…Hence, they naturally cannot target tumor cells. For a targeted drug delivery system, the RBC membrane must get modified with another biomimicking agent, like targeting peptides ( Li et al, 2022a ) or aptamers ( Liu et al, 2022b ).…”

Section: An Overview On Cm-coating Technologymentioning

confidence: 99%

“…Moreover, the aptamer modification increased the survival rate of the intracranial GBM-bearing mice model from 15.5–23 days. Also, the fluorescence imaging results demonstrated the aptamer-modified RBC-membrane coated NPs deep into GBM tissue that successfully accumulated in heterogeneous tumor cells ( Liu et al, 2022b ). This result indicates that CM-NPs could effectively conquer the intratumoral heterogeneity of GBM, which challenged previous treatment efforts.…”

Section: Therapeutic Approaches For Gbm Treatment Via ...mentioning

confidence: 99%

See 2 more Smart Citations

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

Allami

Heidari²,

Rezaei³

2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Glioblastoma multiform (GBM) is the most prevalent and deadliest primary brain malignancy in adults, whose median survival rate does not exceed 15 months after diagnosis. The conventional treatment of GBM, including maximal safe surgery followed by chemotherapy and radiotherapy, usually cannot lead to notable improvements in the disease prognosis and the tumor always recurs. Many GBM characteristics make its treatment challenging. The most important ones are the impermeability of the blood-brain barrier (BBB), preventing chemotherapeutic drugs from reaching in adequate amounts to the tumor site, intratumoral heterogeneity, and roles of glioblastoma stem cells (GSCs). To overcome these barriers, the recently-developed drug-carrying approach using nanoparticles (NPs) may play a significant role. NPs are tiny particles, usually less than 100 nm showing various diagnostic and therapeutic medical applications. In this regard, cell membrane (CM)-coated NPs demonstrated several promising effects in GBM in pre-clinical studies. They benefit from fewer adverse effects due to their specific targeting of tumor cells, biocompatibility because of their CM surfaces, prolonged half-life, easy penetrating of the BBB, and escaping from the immune reaction, making them an attractive option for GBM treatment. To date, CM-coated NPs have been applied to enhance the effectiveness of major therapeutic approaches in GBM treatment, including chemotherapy, immunotherapy, gene therapy, and photo-based therapies. Despite the promising results in pre-clinical studies regarding the effectiveness of CM-coated NPs in GBM, significant barriers like high expenses, complex preparation processes, and unknown long-term effects still hinder its mass production for the clinic. In this regard, the current study aims to provide an overview of different characteristics of CM-coated NPs and comprehensively investigate their application as a novel treatment approach in GBM.

show abstract

Target Reprogramming the 3′UTR of Tumor‐Suppressor Genes by a siRNA Composite Nanoparticle for Glioblastoma Therapy

Gu,

Zeng,

Gong

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most aggressive and common adult brain tumor. Current therapies primarily involve surgical resection, followed by chemotherapy and radiotherapy. However, the low survival rate due to high toxicity, side effects, and poor targeting necessitates novel treatments. Post‐transcriptional regulation pathways, particularly the regulation of alternative polyadenylation based on the mRNA 3′UTR, play a critical role in cell growth and development and the progression of tumors. Targeting tumor cells and reprogramming the 3′UTR of tumor suppressor genes to achieve post‐transcriptional regulation is expected to be a new channel for GBM therapy. Herein, a novel siRNA delivery system is developed based on mesoporous silica nanoparticles: siRNA composite nanoparticles (siRNA CNP). Encapsulation in MSNs overcomes siRNA degradation and cellular entry issues, while lipid bilayer coating improves biocompatibility and stability. Surface‐modified nucleic acid aptamer SL1 (Apt‐SL1) significantly enhances GBM targeting, offering therapeutic potential. The findings show that siRNA CNP effectively silences the promoter CFIm25 of distal poly(A) in tumor cells, inducing gene reprogramming, inhibiting tumor growth, and promoting apoptosis in nude mice. The siRNA CNP demonstrates a significant effect in reprogramming tumor suppressor genes and treating GBM. It offers a novel and promising therapeutic avenue for GBM.

show abstract

Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme

Cited by 7 publications

References 38 publications

Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme

Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

Target Reprogramming the 3′UTR of Tumor‐Suppressor Genes by a siRNA Composite Nanoparticle for Glioblastoma Therapy

Contact Info

Product

Resources

About